Výsledky vyhledávání - "MyungShin Oh"

Akademický článek

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Autor: Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen

Publikováno v: Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)

Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative cl

Externí odkaz: https://doaj.org/article/e2a683879e044250a24f928f8a9a03d4

Zobrazit plný text záznamu

Akademický článek

Global Expression-Based Classification of Lymph Node Metastasis and Extracapsular Spread of Oral Tongue Squamous Cell Carcinoma

Autor: Xiaofeng Zhou, Stephane Temam, Myungshin Oh, Nisa Pungpravat, Bau-Lin Huang, Li Mao, David T. Wong

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 11, Pp 925-932 (2006)

Regional lymph node metastasis is a critical event in oral tongue squamous cell carcinoma (OTSCC) progression. The identification of biomarkers associated with the metastatic process would provide critical prognostic information to facilitate clinica

Externí odkaz: https://doaj.org/article/1d02d553a457422fb9ebc0f6e8807845

Zobrazit plný text záznamu

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Autor: Andrea Everding, Jeffrey Neal, Éva Balázs, Stanley Cohen, Gary Fanjiang, MyungShin Oh, Juan Sánchez-Bursón, Rafal Wojciechowski, Tomas Hala, Mark C. Genovese

Publikováno v: Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Arthritis Research & Therapy

Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fbf5d61aeb8f3faf3de72bad10b3d8
http://link.springer.com/article/10.1186/s13075-020-2142-1

Zobrazit plný text záznamu

AB0377 CLINICAL SIMILARITY OF ABP 710 WITH INFLIXIMAB (REFERENCE PRODUCT) IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

Autor: MyungShin Oh, Jeffrey Neal, Stanley N. Cohen, Gary Fanjiang, Juan Sánchez-Bursón, Éva Balázs, Mark C. Genovese

Publikováno v: Abstracts Accepted for Publication.

Background ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have been shown to be structurally and functionally similar in analytical assessments. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1eb4832212d75ccb2663291beb3ace56
https://doi.org/10.1136/annrheumdis-2019-eular.4928

Zobrazit plný text záznamu

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects

Autor: Melissa A. Gessner, MyungShin Oh, Gary Fanjiang, Vincent Chow

Publikováno v: Clinical Pharmacology in Drug Development

This was a randomized, single‐blind, single‐dose, 3‐arm parallel‐group study. Healthy subjects were randomized to receive ABP 710 (n = 50) or infliximab reference product (RP) sourced from the United States (infliximab US; n = 50) or the Euro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b57886ef7e6937d77c22fa502463c920
https://pubmed.ncbi.nlm.nih.gov/31628783

Zobrazit plný text záznamu

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis

Autor: Erik Berntorp, Bruce M. Ewenstein, Leonard A. Valentino, Gerald Spotts, Krista Fischer, Peter William Collins, Victor S. Blanchette, Steven W. Pipe, Myungshin Oh

Publikováno v: Haemophilia, 22(4), 514. Wiley-Blackwell

Introduction: We previously showed that pharmacokinetic-guided prophylaxis (PKP) allows the dosing interval to be extended while maintaining a specific trough level. However, the associations of peak factor VIII (FVIII) levels and area under the curv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3451c38fcf378938435898aa2fa4d4ef
https://doi.org/10.1111/hae.12905

Zobrazit plný text záznamu

Plný text ve formátu HTML

Recombinant factor IX ( BAX 326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

Autor: B. Valenta-Singer, Miranda Chapman, T. Andreeva, Borislava G. Pavlova, Oleksandra Stasyshyn, Tomasz Urasiński, F. G. Perina, Brigitt E. Abbuehl, L. Rusen, Myungshin Oh

Publikováno v: Haemophilia. 21:196-203

A newly developed recombinant factor IX (BAX326(1) ) was investigated for prophylactic use in paediatric patients aged12 years with severe (FIX level1%) or moderately severe (FIX level 1-2%) haemophilia B. The aim of this prospective clinical trial w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d72260d62f85ba016d7cce2a6de5bc5e
https://doi.org/10.1111/hae.12548

Zobrazit plný text záznamu

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

Autor: B. Valenta-Singer, W. B. Knowlton, Brigitt E. Abbuehl, Tomasz Urasiński, J. L. Lamas, L. Rusen, Margit Serban, F. G. Perina, Borislava G. Pavlova, M. H. Solano Trujillo, Myungshin Oh, Oleksandra Stasyshyn

Publikováno v: Haemophilia. 20:674-681

The ability to switch between coagulation factors safely is of common interest to haemophilia patients and treating physicians. This is the first formal prospective comparative evaluation of safety, efficacy and incremental recovery of a plasma-deriv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cd23a2b42785abbf9ccdf95b441655
https://doi.org/10.1111/hae.12444

Zobrazit plný text záznamu

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Autor: Bruce M. Ewenstein, Myungshin Oh, Sandor Fritsch, Sven Björkman, Kathleen M. Casey, Krista Fischer, Peter William Collins, Gerald Spotts, Victor Blanchette, Phillip Schroth

Publikováno v: Blood. 119:612-618

Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be biased by differences in study protocols, in particular between blood sampling schedules. This could affect clinical dose tailoring, especially in child

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::641a5648fe041e0b6926dff1b949a31a
https://doi.org/10.1182/blood-2011-07-360594

Zobrazit plný text záznamu

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Autor: Bruce M. Ewenstein, Myungshin Oh, Sven Björkman, Gerald Spotts, Victor Blanchette, Phillip Schroth, Kathleen M. Casey, Sandor Fritsch, Krista Fischer, Peter William Collins

Publikováno v: Journal of Thrombosis and Haemostasis, 8(2), 269-275. Wiley

Background: Prophylactic factor (F)VIII has been shown to reduce bleeds and arthropathy in patients with severe hemophilia A. Objectives: Assuming that the trough FVIII level is an important determinant of the efficacy of prophylaxis, this paper addr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e662a088e31befac02f9bdfae67e7fc
https://doi.org/10.1111/j.1538-7836.2009.03703.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání